الفهرس 
INTRODUCTION
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
Prostate cancer is the most common cancer in men in the western countries and represent one of the most important leading cause of cancer death Although there is a good response to the primary hormonal therapy for prostate cancer but later on patients develop a very bad hormone refractory state which greatly affect the patients survival In this issue there are recent trials and researches aiming at developing of new lines of therapy for those patients with hormone refractory stat. In this article there are three drugs that received the FDA approval For the use in patients with prostate cancer which are 1). Cabazitaxel is a new generation of chemotherapy taxene group to be used as a second line chemotherapy after failure of docetaxel.2).proveng is the first immunotherapy that received the FDAapproval to be used in treatment of cancer at all zytiga or (abirterone acetate) is a new hormonal therapy increasing the survival for metastatic hormone refractory patients Also this article shows the role of target therapies like bevacizumab and thalidomide after failure of chemotherapy Recent radiotherapy issues, like the role and the efficacy of the IGRT in increasing the local control of prostate cancer and minimizing the normal tissues toxicity especially to the rectal mucosa, and the benefits of proton therapy which is used firstly in treatment of prostate cancer, also discussed in this article This article also discuss the recent bone targeted therapy like the role of the Denosumabe in improving the pain control and decreased the bone fracture incidence in bone metastatic prostate cancer patients.